Raymond James Reiterates Outperform Rating on Legend Biotech Corp. (LEGN) following Q4

March 10, 2026 3:53 PM

Raymond James analyst Sean McCutcheon reiterated an Outperform rating and $86.00 price target on Legend Biotech Corp. (NASDAQ: LEGN)The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found